# nature portfolio

| Corresponding author(s):   | LOW, Sean  |
|----------------------------|------------|
| Last updated by author(s): | 28.02.2024 |

### **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

| _ |    |    |    |   |                  |
|---|----|----|----|---|------------------|
| 5 | ta | Ť١ | ct | Т | $\cap \subseteq$ |

| For a | all sta   | itistical an | alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.  |  |
|-------|---|--------------|--|--|
| n/a   | Conf  | firmed       |  |  |
| X     |   | The exact    | sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement  |  |
| X     |   | A stateme    | nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |  |
| X     |   |              | ical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.   |  |
| X     | A description of all covariates tested  |              |  |  |
| X     | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |              |  |  |
| X     | 1 1   |              | ription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |  |
| X     | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i> |              |  |  |
| X     |   | For Bayesi   | an analysis, information on the choice of priors and Markov chain Monte Carlo settings   |  |
| X     |   | For hierard  | chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes   |  |
| X     |   | Estimates    | of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |  |
|       |   |              | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.  |  |
| Sof   | twa   | are and      | d code   |  |
| Polic | y info  | ormation a   | about <u>availability of computer code</u>   |  |
| Da    | ta co   | llection     | Zoom (version 5.17.7 (31859))  |  |
| Da    | ta an   | nalysis      | MaxQDA (MAXQDA Standard 2022, Release 22.8.0, (c) 1995-2022 VERBI GmbH Berlin).  |  |
|       |   |              | custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and   |  |

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The datasets generated during and/or analyzed during the current study are not publicly available at present, to allow for further analysis and publication of findings over the course of our multi-year project (European Research Council Grant Agreement No. 951542-GENIE-ERC-2020-SyG). Access to the raw data can be made available from the corresponding author on reasonable request after an embargo of two years, during which time our analysis continues. The totality of the dataset will be made publicly available in full following the conclusion of the GENIE project.

A minimum supporting dataset that is necessary to interpret, verify and extend the research in the article – narrowed from 44 focus group transcripts – is supplied through Supplementary Tables 1-3.

| Research involving hu  | man participants, their data, or biological material   |
|--|--|
|  | with human participants or human data. See also policy information about sex, gender (identity/presentation),  |
| Reporting on sex and gender  | Sex and gender are not considered as part of the analysis of this paper.   |
| Reporting on race, ethnicity, or other socially relevant groupings | Race and ethnicity were not considered as part of the analysis of this paper.  |
| Population characteristics   | Focus groups were screened for an even split between genders, between 18-44 yrs and 45+ yrs cohorts, division between urban and rural, and for distribution across education level, income, occupation type, and region.   |
| Recruitment  | Participants self-defined whether they are climate deniers. Researchers judged this necessary to maintain topical targetedness, as well as goodwill. Participants were screened for an urban (including suburban) or rural background, which was self-defined. These determined if participants might be sorted into Urban or Rural focus groups - |
| Ethics oversight   | but differences between these were not parsed in the present study and play no role in influencing results.  All components of the research were granted ethical approval by the Reseach Ethics Committee of Aarhus University   |
| Note that full information on the appr                             | ov#121211e132 dy protocol must also be provided in the manuscript.   |
| Field-specific re  | porting  |
| Please select the one below that is                                | s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.   |
| Life sciences  | ehavioural & social sciences Ecological, evolutionary & environmental sciences   |
| For a reference copy of the document with                          | all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>  |
| Life sciences stu  | udy design   |
| All studies must disclose on these                                 | points even when the disclosure is negative.   |
| Sample size  |  |
| Data exclusions  |  |
| Replication  |  |
| Randomization  |  |
| Blinding   |  |
|  |  |

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Study description | Qualitative study deploying 44 focus groups in 22 countries to gauge public perceptions on carbon removal technologies  |
|-------------------|---|
| Research sample   | Focus groups were not representive of national populations. Sampling was structured to provide a relatively even spread across population characterics, to foster inclusion and representation across gender, education level, income, occupation type and region |
| Sampling strategy | See below, due to space constraints.  |
| Data collection   | Data was collected by recording over Zoom, and transcribed by Norstat.  |
| Timing            | Data collection proceeded from August to December 2022.   |
| Data exclusions   | No data was excluded.   |
| Non-participation | No participants dropped out or declined participation.  |
| Randomization     | Participants were randomized to the extent that sampling was based on probability sampling and the presence of certain splits and representations of gender, age, locality, education, income, occupation type, and region.                                       |

Sampling strategy: Focus groups sizes aimed at 5-8 participants; standard practice calls for less than 10 in a deliberative engagement. Probability sampling was used, with screening for based on an even split between genders, between 18-44 yrs and 45+ yrs cohorts, division between urban and rural; and for distribution across education level, income brackets, occupation type, and sub-national regions unique to each country. Data saturation was not considered - focus group number and locations were determined beforehand, and were conducted and analyzed to completion. Researchers were not blinded to experimental condition and/or the study hypothesis.

| ll studies must disclose or  | these points even when the disclosure is negative.   |
|--|--|
| Study description  |  |
| Research sample  |  |
| Sampling strategy  |  |
| Data collection  |  |
| Timing and spatial scale   |  |
| Data exclusions  |  |
| Reproducibility  |  |
| Randomization  |  |
| Blinding   |  |
| ield work, collec  | tion and transport   |
| Field conditions  Location   |  |
| Location   |  |
| Location   |  |
| Access & import/export  Disturbance  Reporting formation from a system or method listed is released.   | r specific materials, systems and methods uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each may and to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a respo |
| Location  Access & import/export  Disturbance  Reporting for a control of the require information from a stem or method listed is relevant to the recommendation of the relevant to the relevant to the recommendation of the relevant to the  | uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each ma vant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a respo   |
| Location  Access & import/export  Disturbance  Reporting for a control of the study | uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each may and to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a respo   |
| Location  Access & import/export  Disturbance  Reporting for the require information from a system or method listed is relevant to the study of the  | uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each may and to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a respo   |

### Antibodies

Antibodies used

Validation

| Eukaryotic cell lines                            |   |
|--|---|
| Policy information about <u>cell l</u>           | ines and Sex and Gender in Research   |
| Cell line source(s)                              |   |
| Authentication                                   |   |
| Mycoplasma contamination                         |   |
| Commonly misidentified line (See ICLAC register) | 25  |
| Palaeontology and                                | Archaeology   |
| Specimen provenance                              |   |
| Specimen deposition                              |   |
| Dating methods                                   |   |
| Tick this box to confirm t                       | that the raw and calibrated dates are available in the paper or in Supplementary Information.   |
| Ethics oversight                                 |   |
| Note that full information on the                | approval of the study protocol must also be provided in the manuscript.   |
|  | research organisms  ies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in         |
| <u>Research</u>                                  |   |
| Laboratory animals                               |   |
| Wild animals                                     |   |
| Reporting on sex                                 |   |
| Field-collected samples                          |   |
| Ethics oversight                                 |   |
| Note that full information on the                | approval of the study protocol must also be provided in the manuscript.   |
| Clinical data                                    |   |
| Policy information about clinic                  |   |
| Clinical trial registration                      | th the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions. |
| Study protocol                                   |   |
| Data collection                                  |   |
|  |   |
| Outcomes   |   |

#### Dual use research of concern

Policy information about <u>dual use research of concern</u>

#### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

| No   Yes  |  |  |
|---|--|--|
| X Public health   |  |  |
| X National security   |  |  |
| X Crops and/or livest   | tock   |  |
| X Ecosystems  |  |  |
| X Any other significa   | nt area  |  |
| Experiments of concer   | m  |  |
| Does the work involve an  | y of these experiments of concern:   |  |
| No Yes  |  |  |
| _ _   | to render a vaccine ineffective  |  |
|   | to therapeutically useful antibiotics or antiviral agents                                |  |
|   | ence of a pathogen or render a nonpathogen virulent                                      |  |
| Increase transmissibility of a pathogen   |  |  |
| X Alter the host range of a pathogen  |  |  |
| Enable evasion of diagnostic/detection modalities   Enable the weaponization of a biological agent or toxin |  |  |
| _ _   |  |  |
| X Any other potentia  | ally harmful combination of experiments and agents                                       |  |
|   |  |  |
| Plants  |  |  |
| Seed stocks   |  |  |
| Naval alaut sanat was   |  |  |
| Novel plant genotypes   |  |  |
|   |  |  |
|   |  |  |
| Authentication  |  |  |
|   |  |  |
|   |  |  |
| ChIP-seq  |  |  |
|   |  |  |
| Data deposition   |  |  |
| Confirm that both rav   | v and final processed data have been deposited in a public database such as <u>GEO</u> . |  |
| Confirm that you have   | e deposited or provided access to graph files (e.g. BED files) for the called peaks.     |  |
| Data access links   |  |  |
| May remain private before publi   | cation.  |  |
| Files in database submiss   | ion  |  |
| Genome browser session (e.g. <u>UCSC</u> )  |  |  |
| Methodology   |  |  |
| Replicates  |  |  |
| Sequencing depth  |  |  |
| Antibodies  |  |  |
| Peak calling parameters   |  |  |
| Data quality  |  |  |

| Software  |
|---|
| Flow Cytometry  |
| Plots  Confirm that:  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).  The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).  All plots are contour plots with outliers or pseudocolor plots.  A numerical value for number of cells or percentage (with statistics) is provided. |
| Methodology   |
| Sample preparation  |
| Instrument  |
| Software  |
| Cell population abundance   |
| Gating strategy   |
| Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.   |
| Magnetic resonance imaging  |
| Experimental design   |
| Design type   |
| Design specifications   |
| Behavioral performance measures   |
|   |
| Imaging type(s)   |
| Field strength  |
| Sequence & imaging parameters   |
| Area of acquisition   |
| Diffusion MRI Used Not used   |
| Preprocessing   |
| Preprocessing software  |
| Normalization   |
| Normalization template  |
| Noise and artifact removal  |
| Volume censoring  |
| Statistical modeling & inference  |
| Model type and settings   |
| Effect(s) tested  |
|   |

| <u>re</u>    | nature portfolio |
|--------------|------------------|
| porting summ | reporting summ   |

| $\rightarrow$ |   |
|---------------|---|
|               |   |
| €             |   |
|               |   |
| Š             |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
| ⊱             |   |
| Ņ             |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               | ۱ |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |
|               |   |

| Specify type of analysis:   Whole brain   ROI-based   Both |
|--|
| Statistic type for inference                               |
| (See Eklund et al. 2016)                                   |
| Correction   |
| Models & analysis  |
| n/a   Involved in the study                                |
| Functional and/or effective connectivity                   |
| Graph analysis   |
| Multivariate modeling or predictive analysis               |
| Functional and/or effective connectivity                   |
| Graph analysis   |
| Multivariate modeling and predictive analysis              |